Apolipoprotein (a) levels in type 1 and type 2 diabetes mellitus.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print Cited Medium: Print ISSN: 0940-5429 (Print) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Lipoprotein(a)*; Apolipoproteins/*blood ; Diabetes Mellitus, Type 1/*blood ; Diabetes Mellitus, Type 2/*blood ; Diabetic Angiopathies/*diagnosis; Adult ; Aged ; Apoprotein(a) ; Biomarkers/blood ; Cholesterol/blood ; Cholesterol, HDL/blood ; Diabetic Angiopathies/blood ; Female ; Humans ; Male ; Middle Aged ; Reference Values ; Risk Factors ; Triglycerides/blood

Type 1 and type 2 diabetes mellitus are both characterized by increased cardiovascular mortality and morbidity. Since several reports have indicated that apolipoprotein (a) [apo(a)] levels are positively associated with an increased risk of macrovascular disease, we investigated whether apo(a) levels are elevated in both types of diabetes mellitus and may thus represent an independent risk factor for atherosclerotic disease. Apo(a) concentrations in type 1 diabetic patients were not significantly different from matched controls (276 +/- 78 vs 149 +/- 46 units/l). Type 2 diabetic patients had considerably higher levels of apo(a) than matched controls (471 +/- 89 vs 221 +/- 61 units/l, P = 0.06), though the difference was not statistically significant. However, concentrations of apo(a) were above 300 units/l in 36% of type 1 and 67% of type 2 diabetic patients, but in only 14% and 25% respectively of matched control subjects. Plasma triglycerides were positively and independently correlated with apo(a) levels in both diabetic and non-diabetic subjects. On the other hand, no significant correlation was found between apo(a) levels and glycosylated haemoglobin, total cholesterol or high density lipoprotein cholesterol in any of the groups studied. In conclusion, apo(a) levels are not significantly elevated either in type 1 or type 2 diabetic patients without proteinuria and in moderate metabolic control; however, levels above 300 units/l were 2.6 times more frequent in both types of diabetes mellitus than in carefully age-, sex-, and weight-matched control subjects.

J Biol Chem. 1984 Sep 25;259(18):11470-8. (PMID: 6236225)
Arch Intern Med. 1972 Dec;130(6):833-43. (PMID: 5082462)
J Clin Invest. 1986 Feb;77(2):622-30. (PMID: 2935560)
J Clin Invest. 1987 Aug;80(2):458-65. (PMID: 2956279)
Gerontology. 1982 Nov-Dec;28(6):381-5. (PMID: 6219044)
Diabetes Care. 1991 Apr;14(4):283-7. (PMID: 1829404)
Acta Pathol Microbiol Scand. 1963;59:369-82. (PMID: 14064818)
JAMA. 1990 Jan 5;263(1):35-6. (PMID: 2136711)
J Clin Invest. 1990 Jun;85(6):1709-15. (PMID: 2140835)
J Clin Invest. 1980 Jun;65(6):1483-90. (PMID: 7410552)
N Engl J Med. 1990 May 24;322(21):1494-9. (PMID: 2139920)
Diabetes Care. 1991 Apr;14(4):302-7. (PMID: 1829405)
Methods Enzymol. 1986;128:354-64. (PMID: 3724512)
Atherosclerosis. 1981 Jan-Feb;38(1-2):51-61. (PMID: 7470205)
Clin Genet. 1974;6(3):230-5. (PMID: 4372011)
Diabetologia. 1987 Mar;30(3):144-8. (PMID: 3582820)
J Lipid Res. 1991 Apr;32(4):679-83. (PMID: 1830325)
Circulation. 1986 Oct;74(4):758-65. (PMID: 2944670)
Atherosclerosis. 1986 Dec;62(3):249-57. (PMID: 2948513)
Clin Genet. 1975 Sep;8(3):183-9. (PMID: 170031)
Lancet. 1988 May 14;1(8594):1070-3. (PMID: 2896911)
Science. 1989 Nov 17;246(4932):904-10. (PMID: 2530631)
Br Med J (Clin Res Ed). 1983 Sep 24;287(6396):867-70. (PMID: 6412862)
Atherosclerosis. 1983 Dec;49(3):277-93. (PMID: 6229255)
JAMA. 1986 Nov 14;256(18):2540-4. (PMID: 2945939)

0 (Apolipoproteins)
0 (Biomarkers)
0 (Cholesterol, HDL)
0 (Lipoprotein(a))
0 (Triglycerides)
97C5T2UQ7J (Cholesterol)
EC 3.4.21.- (Apoprotein(a))

Date Created: 19910101 Date Completed: 19920309 Latest Revision: 20191028

20221213

10.1007/BF00579719

1777652